Gaush Meditech

Gaush Meditech EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Gaush Meditech (2407.HK) as of Nov 14, 2026 is 121.65 M CNY. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 168.67 M CNY — a change of -27.88% (lower).

EBITDA

121.65 MCNY

YoY

-27.88%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Gaush Meditech is 2025 121.65 M CNY. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Gaush Meditech was 2024 168.67 M CNY. It decreases by -27.88% lower compared to the previous year.

The Gaush Meditech EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2019
152.03 M CNY
Jan 1, 2020
155.79 M CNY
Jan 1, 2021
219.94 M CNY
Jan 1, 2022
210.62 M CNY
Jan 1, 2023
238.79 M CNY
Jan 1, 2024
168.67 M CNY
Jan 1, 2025
121.65 M CNY
The Gaush Meditech EBITDA history
YEAREBITDAYoY
121.65 MCNY-27.88%
168.67 MCNY-29.36%
238.79 MCNY+13.37%
210.62 MCNY-4.24%
219.94 MCNY+41.17%
155.79 MCNY+2.48%
152.03 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Gaush Meditech Stock analysis

What does Gaush Meditech do? Gaush Meditech Ltd. generates revenue through four business segments. The Proprietary Products segment develops and sells surgical equipment, intraocular lenses, and diagnostic and treatment devices for ophthalmic diseases, along with related software and consumables. The Distribution segment distributes branded ophthalmic medical devices and consumables. The Technical Services segment offers after-sales services including warranty, maintenance, and consumables support. The Others segment handles equipment leasing and intellectual property agency services. Products are used in treating conditions like cataracts, glaucoma, and pediatric ophthalmology across various medical specialties. The company's primary customers include hospitals, clinics, and medical institutions specializing in ophthalmology. These institutions purchase proprietary devices, branded consumables, and technical support services. The firm's focus on ophthalmic subspecialties ensures consistent demand for its products and services in the treatment of eye diseases. Revenue streams are diversified across product development, distribution, and post-sale services. The proprietary segment drives innovation with surgical equipment and lenses, while distribution and technical services provide steady income from established medical partners. Equipment leasing and IP services in the Others segment contribute to additional revenue without requiring direct product sales. Gaush Meditech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Gaush Meditech stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Gaush Meditech is 121.65 M CNY in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Gaush Meditech changed from 168.67 M CNY to 121.65 M CNY, representing a -27.88% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Gaush Meditech since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Gaush Meditech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Gaush Meditech

All Key Metrics — Gaush Meditech